EX-99.2

Exhibit 99.2

SCHERING-PLOUGH CORPORATION
STATEMENTS OF CONSOLIDATED OPERATIONS
(Dollars in Millions, except EPS)
(Unaudited)


	2006															2005
	1st			2nd			3rd			4th			Full				1st			2nd			3rd			4th			Full			4th Qtr.			12 Mos.
	Qtr.			Qtr.			Qtr.			Qtr.			Year				Qtr.			Qtr.			Qtr.			Qtr.			Year			vs			vs
	$			$			$			$			$				$			$			$			$			$			4^th Qtr.			12 Mos.

Net sales 1/		2,551			2,818			2,574			2,650			10,594				2,369			2,532			2,284			2,324			9,508			14	%		11	%

Cost of sales 2/		893			1,004			885			915			3,697				889			867			775			815			3,346			12	%		10	%

Gross profit		1,658			1,814			1,689			1,735			6,897				1,480			1,665			1,509			1,509			6,162			15	%		12	%

Selling, general and administrative		1,086			1,224			1,158			1,250			4,718				1,081			1,116			1,064			1,114			4,374			12	%		8	%
Research and development 3/		481			539			536			631			2,188				384			442			566			474			1,865			33	%		17	%
Other (income)/expense, net		(34	)		(19	)		(37	)		(46	)		(135	)			17			(8	)		—			(5	)		5			*			*
Special charges 4/		—			80			10			12			102				27			259			6			2			294			*			(65	%)
Equity income from cholesterol joint venture		(311	)		(355	)		(390	)		(403	)		(1,459	)			(220	)		(170	)		(215	)		(268	)		(873	)		50	%		67	%

Income before income taxes		436			345			412			291			1,483				191			26			88			192			497			51	%		*

Income tax expense 5/		86			86			103			87			362				64			74			23			66			228			32	%		59	%

Net income/(loss) before cumulative effect of a change in accounting principle		350			259			309			204			1,121				127			(48	)		65			126			269			61	%		*

Cumulative effect of a change in accounting principle, net of tax 6/		(22	)		—			—			—			(22	)			—			—			—			—			—			—			*

Net income/(loss) 6/		372			259			309			204			1,143				127			(48	)		65			126			269			61	%		*

Preferred stock dividends		22			22			22			22			86				22			22			22			22			86			—			—

Net income/(loss) available to common shareholders 6/		350			237			287			182			1,057				105			(70	)		43			104			183			74	%		*


Diluted earnings/(loss) per common share:
Earnings/(loss) available to common shareholders before cumulative effect of a change in accounting principle		0.22			0.16			0.19			0.12			0.69				0.07			(0.05	)		0.03			0.07			0.12
Cumulative effect of a change in accounting principle, net of tax 6/		0.02			0.00			0.00			0.00			0.02				—			—			—			—			—

Diluted earnings/(loss) per common share 6/		0.24			0.16			0.19			0.12			0.71				0.07			(0.05	)		0.03			0.07			0.12


Avg. shares outstanding- diluted		1,486			1,489			1,492			1,497			1,491				1,480			1,476			1,487			1,487			1,484
Actual shares outstanding		1,481			1,481			1,483			1,487			1,487				1,475			1,476			1,478			1,479			1,479



Ratios to net sales
Net sales		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%			100.0	%		100.0	%		100.0	%		100.0	%		100.0	%
Cost of sales		35.0	%		35.6	%		34.4	%		34.5	%		34.9	%			37.5	%		34.2	%		34.0	%		35.1	%		35.2	%
Gross margin		65.0	%		64.4	%		65.6	%		65.5	%		65.1	%			62.5	%		65.8	%		66.0	%		64.9	%		64.8	%
Selling, general and administrative		42.6	%		43.4	%		45.0	%		47.2	%		44.5	%			45.6	%		44.1	%		46.6	%		47.9	%		46.0	%
Research and development		18.8	%		19.1	%		20.8	%		23.8	%		20.6	%			16.2	%		17.4	%		24.8	%		20.4	%		19.6	%
Income before income taxes		17.1	%		12.2	%		16.0	%		11.0	%		14.0	%			8.0	%		1.0	%		3.8	%		8.3	%		5.2	%
Net income/(loss)		14.6	%		9.2	%		12.0	%		7.7	%		10.8	%			5.3	%		(1.9	%)		2.8	%		5.4	%		2.8	%


*		Not a meaningful percentage

		Note: The Company incurs substantial costs, such as selling, general and administrative costs, that are not reflected in the “Equity income from cholesterol joint venture” and are borne by the overall cost structure of Schering-Plough.

1/		Net sales for the three months ended September 30, 2006, includes $47 million related to the reversal of previously accrued rebate amounts for the U.S. Government’s TRICARE Retail Pharmacy Program that a U.S. Federal court has ruled pharmaceutical manufacturers are not obligated to pay.

2/		Included in Cost of sales for the three months ended December 31, 2006 is $45 million of accelerated depreciation and other charges related to the manufacturing changes announced on June 1, 2006. Cost of sales for the twelve months ended December 31, 2006 included $146 million of inventory write-offs, accelerated depreciation and other charges related to the manufacturing changes.

3/		Included in research and development for the three and twelve months ended December 31, 2006 is $15 million for the licensing of an OTC version of ZEGERID for heartburn.

4/		Special charges in the fourth quarter of 2006 reflect severance of $12 million related to the manufacturing changes announced on June 1, 2006. Special charges of $102 million for the twelve months ended December 31, 2006 include severance and fixed asset write-offs related to the manufacturing changes. Special charges for the twelve months ended December 31, 2005 included an addition of $250 million to the Company’s litigation reserves relating to the Massachusetts investigation and previously disclosed investigations and litigation relating to the company’s practices regarding average wholesale price by the Department of Justice and certain states.

5/		Tax expense for all periods presented primarily relates to foreign tax expense as the Company did not recognize the benefit of U.S. tax operating losses. The Company’s full year 2005 tax provision included a benefit of approximately $42 million related to tax expense recorded in 2004 related to planned earnings repatriations under the American Jobs Creation Act (AJCA). This adjustment of tax expense associated with repatriation under the AJCA is the result of an IRS Notice issued by the U.S. Treasury in August 2005.

6/		In the first quarter of 2006, the Company adopted the provisions of SFAS 123R. As a result of this adoption, the Company recognized a non-recurring cumulative effect adjustment of $22 million of income associated with the Company’s liability based compensation plans. Stock option expense for the three and twelve months ended December 31, 2006 was $14 million and $56 million, respectively, which is included in the respective expense line items.

		All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 1

SCHERING-PLOUGH CORPORATION
CONSOLIDATED SALES
(Dollars in Millions)


	2006										2005
	1st		2nd		3rd		4th		Full			1st		2nd		3rd		4th		Full		4th Qtr.			12 Mos.
	Qtr.		Qtr.		Qtr.		Qtr.		Year			Qtr.		Qtr.		Qtr.		Qtr.		Year		vs			vs
	$		$		$		$		$			$		$		$		$		$		4th Qtr.			12 Mos.

*Prescription Pharm:*		*2,032*		*2,230*		*2,087*		*2,211*		*8,561*			*1,846*		*1,975*		*1,840*		*1,904*		*7,564*		16	%		13	%
U.S.		656		718		733		800		2,908			549		609		597		600		2,355		33	%		23	%
International		1,376		1,512		1,354		1,411		5,653			1,297		1,366		1,243		1,304		5,209		8	%		9	%



*Consumer Health Care:*		*311*		*349*		*259*		*205*		*1,123*			*330*		*330*		*235*		*198*		*1,093*		4	%		3	%

*OTC:*		*153*		*149*		*138*		*118*		*558*			*162*		*162*		*129*		*103*		*556*		15	%		—
OTC Claritin		111		111		95		72		390			116		133		92		54		394		35	%		(1	%)
Other OTC		42		38		43		46		168			46		29		37		49		162		(7	%)		4	%

*Foot Care:*		83		96		92		73		*343*			84		89		85		75		*333*		(3	%)		3	%

*Sun Care:*		75		*104*		29		14		*222*			84		79		21		20		*204*		*(31*	%)		9	%



*Animal Health:*		*208*		*239*		*228*		*234*		*910*			*193*		*227*		*209*		*222*		*851*		6	%		7	%
U.S.		57		62		72		50		240			44		54		68		50		216		—			11	%
International		151		177		156		184		670			149		173		141		172		635		7	%		5	%



*Total Consolidated:*		*2,551*		*2,818*		*2,574*		*2,650*		*10,594*			*2,369*		*2,532*		*2,284*		*2,324*		*9,508*		14	%		11	%

U.S.		999		1,103		1,047		1,043		4,192			897		970		886		837		3,589		25	%		17	%
International		1,552		1,715		1,527		1,607		6,402			1,472		1,562		1,398		1,487		5,919		8	%		8	%

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 2

SCHERING-PLOUGH CORPORATION
PRESCRIPTION PHARMACEUTICAL SALES — KEY PRODUCT SALES
(Dollars in Millions)


	Global Prescription Pharm								U.S.									International
	2006		2005						2006			2005						2006			2005
	4th			4th		4th Qtr.				4th			4th		4th Qtr.				4th			4th		4th Qtr.
	Qtr.			Qtr.		vs				Qtr.			Qtr.		vs				Qtr.			Qtr.		vs
	$			$		4th Qtr.				$			$		4th Qtr.				$			$		4th Qtr.

*Prescription Pharm:*		*2,211*			*1,904*		16	%			*800*			*600*		33	%			*1,411*			*1,304*		8	%

Remicade		337			251		34	%			—			—		—				337			251		34	%
Nasonex		253			185		37	%			171			115		48	%			82			70		18	%
PEG-Intron		208			214		(3	%)			49			52		(6	%)			159			162		(2	%)
Clarinex / Aerius		164			139		18	%			94			76		24	%			70			63		12	%
Temodar		189			160		18	%			74			73		1	%			115			87		32	%
Claritin Rx		78			85		(8	%)			—			—		—				78			85		(8	%)
Integrilin		85			71		20	%			81			67		21	%			4			4		—
Rebetol		75			94		(21	%)			2			4		(49	%)			73			90		(20	%)
Avelox 1/		103			68		51	%			103			68		51	%			—			—		—
Intron A		57			66		(14	%)			29			32		(9	%)			28			34		(19	%)
Caelyx		49			46		8	%			—			—		—				49			46		8	%
Subutex		51			49		4	%			—			—		—				51			49		4	%
Elocon		33			32		5	%			1			—		—				32			32		—
Cipro 1/		25			33		(24	%)			25			33		(24	%)			—			—		—


1/		Includes net sales in Puerto Rico

		All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 3

SCHERING-PLOUGH CORPORATION
GLOBAL PRESCRIPTION PHARMACEUTICAL SALES — KEY PRODUCT SALES
(Dollars in Millions)


	2006										2005
	1st		2nd		3rd		4th		Full			1st		2nd		3rd		4th		Full		4th Qtr.			12 Mos.
	Qtr.		Qtr.		Qtr.		Qtr.		Year			Qtr.		Qtr.		Qtr.		Qtr.		Year		vs			vs
	$		$		$		$		$			$		$		$		$		$		4th Qtr.			12 Mos.

*Global Prescription Pharm:*		*2,032*		*2,230*		*2,087*		*2,211*		*8,561*			*1,846*		*1,975*		*1,840*		*1,904*		*7,564*		16	%		13	%

Remicade		278		307		317		337		1,240			220		234		237		251		942		34	%		32	%
Nasonex		229		242		221		253		944			183		199		170		185		737		37	%		28	%
PEG-Intron		196		226		206		208		837			170		182		185		214		751		(3	%)		11	%
Clarinex / Aerius		160		226		171		164		722			144		207		157		139		646		18	%		12	%
Temodar		163		171		179		189		703			131		145		152		160		588		18	%		20	%
Claritin Rx		101		104		74		78		356			111		100		76		85		371		(8	%)		(4	%)
Integrilin		80		82		82		85		329			75		82		86		71		315		20	%		5	%
Rebetol		78		86		72		75		311			64		91		82		94		331		(21	%)		(6	%)
Avelox 1/		80		58		63		103		304			73		46		41		68		228		51	%		34	%
Intron A		60		64		57		57		237			73		75		72		66		287		(14	%)		(17	%)
Caelyx		51		53		52		49		206			43		46		46		46		181		8	%		13	%
Subutex		48		53		51		51		203			51		53		44		49		197		4	%		3	%
Elocon		34		38		36		33		141			41		38		34		32		144		5	%		(2	%)
Cipro 1/		25		34		28		25		111			37		36		41		33		146		(24	%)		(24	%)


1/		Includes net sales in Puerto Rico

		All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 4

SCHERING-PLOUGH CORPORATION
U.S. PHARMACEUTICAL SALES — KEY PRODUCT SALES
(Dollars in Millions)


	2006										2005
	1st		2nd		3rd		4th		Full			1st		2nd		3rd		4th		Full		4th Qtr.			12 Mos.
	Qtr.		Qtr.		Qtr.		Qtr.		Year			Qtr.		Qtr.		Qtr.		Qtr.		Year		vs			vs
	$		$		$		$		$			$		$		$		$		$		4th Qtr.			12 Mos.

*Total U.S. Pharm:*		*656*		*718*		*733*		*800*		*2,908*			*549*		*609*		*597*		*600*		*2,355*		33	%		23	%

Nasonex		144		144		153		171		611			109		115		109		115		447		48	%		37	%
PEG-Intron		43		57		51		49		201			52		38		42		52		184		(6	%)		9	%
Clarinex / Aerius		70		97		98		94		358			67		90		93		76		325		24	%		10	%
Temodar		67		72		72		74		286			57		65		70		73		264		1	%		8	%
Integrilin		76		78		78		81		312			71		78		82		67		299		21	%		5	%
Avelox 1/		80		58		63		103		304			73		46		41		68		228		51	%		34	%
Intron A		30		33		28		29		120			32		36		36		32		136		(9	%)		(12	%)
Elocon		—		1		1		1		3			4		2		1		—		7		—			(52	%)
Cipro 1/		25		34		28		25		111			37		36		41		33		146		(24	%)		(24	%)


1/		Includes net sales in Puerto Rico

		All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 5

SCHERING-PLOUGH CORPORATION
INTERNATIONAL PHARMACEUTICAL SALES — KEY PRODUCT SALES
(Dollars in Millions)


	2006										2005
	1st		2nd		3rd		4th		Full			1st		2nd		3rd		4th		Full		4th Qtr.			12 Mos.
	Qtr.		Qtr.		Qtr.		Qtr.		Year			Qtr.		Qtr.		Qtr.		Qtr.		Year		vs			vs
	$		$		$		$		$			$		$		$		$		$		4th Qtr.			12 Mos.

*Total International Pharm:*		*1,376*		*1,512*		*1,354*		*1,411*		*5,653*			*1,297*		*1,366*		*1,243*		*1,304*		*5,209*		8	%		9	%

Remicade		278		307		317		337		1,240			220		234		237		251		942		34	%		32	%
Nasonex		85		98		68		82		333			74		84		61		70		290		18	%		15	%
PEG-Intron		153		169		155		159		636			118		144		143		162		567		(2	%)		12	%
Clarinex / Aerius		90		129		73		70		364			77		117		64		63		321		12	%		13	%
Temodar		96		99		107		115		417			74		80		82		87		324		32	%		29	%
Claritin Rx		101		104		74		78		356			111		100		76		85		371		(8	%)		(4	%)
Integrilin		4		4		4		4		17			4		4		4		4		16		—			5	%
Rebetol		76		84		72		73		306			70		90		80		90		330		(20	%)		(7	%)
Intron A		30		31		29		28		117			41		39		36		34		151		(19	%)		(22	%)
Caelyx		51		53		52		49		206			43		46		46		46		181		8	%		13	%
Subutex		48		53		51		51		203			51		53		44		49		197		4	%		3	%
Elocon		34		37		35		32		138			37		36		33		32		137		—			—

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 6

SCHERING-PLOUGH CORPORATION
CHOLESTEROL FRANCHISE SALES
(Dollars in Millions)


	2006										2005
	1st		2nd		3rd		4th		Full			1st		2nd		3rd		4th		Full		4th Qtr.			12 Mos.
	Qtr.		Qtr.		Qtr.		Qtr.		Year			Qtr.		Qtr.		Qtr.		Qtr.		Year		vs			vs
	$		$		$		$		$			$		$		$		$		$		4th Qtr.			12 Mos.

*Global Zetia: 1/*		*415*		*474*		*501*		*535*		*1,925*			*331*		*317*		*357*		*392*		*1,396*		36	%		38	%
U.S.		315		363		389		405		1,472			269		240		277		297		1,082		36	%		36	%
International		100		111		112		130		453			62		77		80		95		314		37	%		44	%

*Global Vytorin: 1/*		*371*		*491*		*517*		*554*		*1,933*			*178*		*201*		*265*		*368*		*1,012*		51	%		91	%
U.S.		319		421		431		448		1,619			157		173		229		314		874		43	%		85	%
International		52		70		86		106		314			21		28		36		54		138		96	%		128	%

*Global Cholesterol: 1/ 2/*		*786*		*965*		*1,018*		*1,089*		*3,858*			*509*		*518*		*622*		*760*		*2,408*		43	%		60	%
U.S.		634		784		820		852		3,091			426		413		506		611		1,956		39	%		58	%
International		152		181		198		237		767			83		105		116		149		452		59	%		70	%


1/		Substantially all sales of cholesterol products are not included in the Company’s net sales. Global sales include sales under the Merck/Schering-Plough partnership, plus any sales that are not part of the partnership, such as Schering-Plough sales of cholesterol products in Latin America. In the fourth quarter of 2006 and 2005, sales in non-joint venture territories of the cholesterol franchise totaled $7 and $5, respectively. For the twelve months of 2006 and 2005, sales in non-joint venture territories of the cholesterol franchise totaled $29 and $19, respectively.

2/		Global cholesterol franchise sales for the three months ended September 30, 2006 includes approximately $24 million related to the reversal of previously accrued rebate amounts for a U.S Government prescription pharmaceutical program (the “TRICARE Retail Pharmacy Program”) that a U.S. Federal court ruled pharmaceutical manfacturers are not obligated to pay.

		The results of the operation of the joint venture are reflected in equity income. As a result, the Company’s gross margin and ratios of selling, general and administrative expenses and R&D expenses as a percentage of sales do not reflect the impact of the cholesterol joint venture’s operating results.

		The company utilizes the equity method of accounting for the joint venture. The cholesterol agreements provide for the sharing of net income/(loss) based upon percentages that vary by product, sales level and country. In the U.S. market, Schering-Plough receives a greater share of profits on the first $300 of annual ZETIA sales. Above $300 of annual ZETIA sales, the companies share profits equally. Schering-Plough’s allocation of joint venture income is increased by milestones earned. Further, either partner’s share of the joint venture’s net income/(loss) is subject to a reduction if the partner fails to perform a specified minimum number of physician details in a particular country. The partners agree annually to the minimum number of physician details by country.

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 7

SCHERING-PLOUGH CORPORATION
CONSOLIDATED OPERATIONS DATA
(Dollars in Millions)
(Unaudited)


	2006															2005
	1st			2nd			3rd			4th			Full				1st			2nd			3rd			4th			Full
	Qtr.			Qtr.			Qtr.			Qtr.			Year				Qtr.			Qtr.			Qtr.			Qtr.			Year
	$			$			$			$			$				$			$			$			$			$

Geographic sales

U.S.		999			1,103			1,047			1,043			4,192				897			970			886			837			3,589
Europe and Canada		1,046			1,206			1,044			1,107			4,403				1,035			1,102			927			976			4,040
Latin America		260			248			233			249			990				210			218			223			233			884
Asia Pacific		246			261			250			251			1,009				227			242			248			278			995

Consolidated sales		2,551			2,818			2,574			2,650			10,594				2,369			2,532			2,284			2,324			9,508

	2006															2005
	1st			2nd			3rd			4th			Full				1st			2nd			3rd			4th			Full
	Qtr.			Qtr.			Qtr.			Qtr.			Year				Qtr.			Qtr.			Qtr.			Qtr.			Year
	$			$			$			$			$				$			$			$			$			$

Other (income)/expense, net
Interest income		(68	)		(69	)		(77	)		(83	)		(297	)			(33	)		(40	)		(45	)		(58	)		(176	)
Interest expense		46			45			40			41			172				45			40			36			41			163
FX losses		—			5			—			(4	)		2				4			1			2			2			8
Other (income)/expense		(12	)		—			—			—			(12	)			1			(9	)		7			10			10

Total — Other (income)/expense, net		(34	)		(19	)		(37	)		(46	)		(135	)			17			(8	)		—			(5	)		5

All figures rounded. Totals may not add due to rounding.

Page 8